Tosedostat

Tosedostat (CHR-2797) is an orally active aminopeptidase inhibitor. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines[1].

Product Specifications

CAS Number

[238750-77-1]

Product Name Alternative

CHR-2797

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aminopeptidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Tosedostat.html

Concentration

10mM

Purity

99.68

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OC1CCCC1)[C@@H](NC([C@@H]([C@H](O)C(NO)=O)CC(C)C)=O)C2=CC=CC=C2

Molecular Formula

C21H30N2O6

Molecular Weight

406.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Krige D, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68 (16) :6669-79.|[2]Jenkins C, et al. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leuk Res. 2011 May;35 (5) :677-81.|[3]Smith EM, et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget. 2015 Jul 10;6 (19) :17314-27.|[4]Emma M Smith, et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget. 2015 Jul 10;6 (19) :17314-27.